• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
February 19, 2019 10:21 AM EST
News Briefing

Ab­b­Vie scores speedy re­view for RA drug upadac­i­tinib; Mer­ck KGaA wins CRISPR patent

Natalie Grover

Reporter

→ Ab­b­Vie $AB­BV has high hopes, pro­ject­ing peak po­ten­tial sales of $6.5 bil­lion, for its oral JAK1 in­hibitor upadac­i­tinib for rheuma­toid arthri­tis, which is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now
TRENDING NOW

Kennedy's vac­cine doubts hinge on 'in­ert' place­bos, but ex­perts say he mis­un­der­stands the sci­ence

Ex­clu­sive: Kennedy picks for vac­cine ad­vi­so­ry board were paid ex­perts against Mer­ck in civ­il cas­es

Cure­Vac CEO on BioN­Tech deal: Come to­geth­er 'rather than fight­ing each oth­er in court'

In sur­prise, FDA ap­proves Uro­Gen's chemo-turned-gel drug af­ter neg­a­tive ad­comm vote

In­smed aims to raise $750M in one of the largest stock of­fer­ings this year

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times